Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRAVELLE vs DANOCRINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.
Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.
Ovulation induction in anovulatory women with polycystic ovary syndrome (PCOS),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
Treatment of endometriosis amenable to hormonal management,Management of fibrocystic breast disease,Hereditary angioedema (prophylaxis of attacks)
For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.
100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.
Terminal elimination half-life approximately 5-6 hours in healthy adults. Extended in renal impairment (up to 24 hours with Cr Cl <30 m L/min).
Terminal elimination half-life: 10–30 hours (mean 15 hours); clinically, steady-state reached after 2–4 days.
Primarily metabolized in the liver via renal excretion; metabolic pathways not fully characterized.
Danazol is extensively metabolized in the liver via hydroxylation and conjugation. It is a substrate of CYP3A4 and may inhibit CYP3A4, CYP2C9, and CYP2C19. The major metabolites include 2-hydroxymethylethisterone and ethisterone, which exhibit some androgenic activity.
Primarily renal: 95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal: 5% eliminated via feces.
Renal (metabolites, ~50%), biliary/fecal (~30%), unchanged drug minimal.
Approximately 10-20% bound to plasma proteins (albumin and α-1 acid glycoprotein).
~80–90%, primarily to albumin and sex hormone-binding globulin (SHBG).
Approximately 0.3-0.5 L/kg. Distributing primarily in extracellular fluid; does not extensively penetrate tissues.
Vd ~0.5–1.0 L/kg; moderate tissue distribution.
Subcutaneous: 90-95% bioavailable relative to intramuscular route. Oral: not clinically used due to enzymatic degradation.
Oral: ~80–100% (well absorbed).
No specific guidelines exist for GFR-based dose modifications; use with caution in severe renal impairment (Cr Cl <30 m L/min) and monitor for adverse effects.
No specific guidelines; use with caution in renal impairment. Monitor fluid balance and renal function.
No specific guidelines exist for Child-Pugh based modifications; use with caution in severe hepatic impairment and monitor for adverse effects.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, use reduced dose and monitor liver function; avoid in active liver disease.
Not indicated for use in pediatric patients; safety and efficacy not established.
Not recommended for use in pediatric patients due to potential for premature epiphyseal closure and other adverse effects.
Not indicated for use in geriatric patients; safety and efficacy not established.
No specific dosing adjustments; use lowest effective dose due to potential for increased sensitivity to androgenic effects and hepatic metabolism changes.
Bravelle should only be used by physicians who are experienced in infertility treatment and can manage potential serious adverse events, including ovarian hyperstimulation syndrome (OHSS) and multiple gestations.
None
Ovarian enlargement and ovarian hyperstimulation syndrome (OHSS) – can lead to serious complications; discontinue treatment if OHSS is suspected.,Multiple gestations – increased risk of multiple births.,Ovarian torsion – report sudden abdominal pain.,Pulmonary and vascular complications – thromboembolic events; discontinue if suspected.,Ectopic pregnancy and spontaneous abortion – higher rates in ART patients.,Neoplasms – risk of ovarian neoplasms with repeated use.
Risk of thromboembolic events (DVT, pulmonary embolism),Hepatotoxicity (elevated liver enzymes, jaundice, peliosis hepatis, benign hepatic adenoma),Intracranial hypertension (pseudotumor cerebri),Androgenic effects (acne, hirsutism, voice deepening, weight gain, clitoral hypertrophy),Carcinogenicity (increased risk of hepatocellular carcinoma),Use in pregnancy causes pseudothermalphroditism in female fetuses,May suppress the immune system; increased risk of infections,Can cause pancreatitis, hyperglycemia, and insulin resistance,May increase LDL and decrease HDL cholesterol,Monitor liver function, lipid profile, and signs of thrombosis
Hypersensitivity to urofollitropin or any component,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Known or suspected pregnancy,Ovarian cyst or enlargement of undetermined origin,Abnormal uterine bleeding of undetermined origin,Sex hormone-dependent tumors (e.g., breast, uterus, ovary)
Undiagnosed abnormal genital bleeding,Severely impaired hepatic, renal, or cardiac function,Pregnancy or breastfeeding,Porphyria,Androgen-dependent tumors (e.g., prostate carcinoma),Breast cancer in males,History of thromboembolic disease,Hypersensitivity to danazol or components
No known food interactions. Maintain normal diet and hydration. Avoid alcohol as it may exacerbate side effects like nausea.
No significant food interactions. Grapefruit juice may affect metabolism; advise caution.
Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Second and third trimesters: No direct fetal effects reported, but risks associated with multiple gestation (preterm birth, low birth weight). Maternal OHSS may lead to thromboembolism.
Danocrine (danazol) is contraindicated in pregnancy. It is an androgen derivative and can cause virilization of the female fetus, including clitoromegaly, labial fusion, and urogenital sinus abnormalities. Risk is highest during the first trimester when genital differentiation occurs; exposure at any gestational age may result in androgenic effects.
Urofollitropin is not indicated for use during lactation. No data on excretion in human milk, M/P ratio not established. Use during breastfeeding is contraindicated due to potential for adverse effects on infant hormone levels.
Danazol is excreted into breast milk. The M/P ratio is unknown. Due to potential androgenic effects in the nursing infant (e.g., virilization), breastfeeding is not recommended during danocrine therapy.
No dose adjustment applicable as therapy is discontinued upon confirmed pregnancy. No pharmacokinetic data during pregnancy; drug is not used after conception due to contraindication.
Danocrine is contraindicated in pregnancy. No dose adjustment is applicable; therapy must be discontinued immediately if pregnancy is suspected or confirmed. Pharmacokinetic changes in pregnancy are not relevant due to contraindication.
BRAVELLE (urofollitropin) is a purified FSH product used for controlled ovarian hyperstimulation. Administer subcutaneously; rotate injection sites. Monitor estradiol levels and follicle growth via ultrasound. Risk of ovarian hyperstimulation syndrome (OHSS); consider using Gn RH antagonist protocols to reduce risk. Do not administer if patient has high baseline FSH levels (>15 IU/L) indicating poor ovarian reserve.
Danocrine suppresses pituitary-ovarian axis by inhibiting gonadotropin release; monitor liver function, lipid profile, and for signs of virilization. Avoid in pregnancy and porphyria.
Teach proper injection technique and site rotation (abdomen, thigh).,Report immediately if severe pelvic pain, nausea, vomiting, or rapid weight gain occurs (OHSS signs).,Avoid intercourse until instructed to prevent multiple pregnancy.,Inform of multiple pregnancy risk (especially twins).,Store vials in refrigerator (2-8°C) and protect from light.
Take with food to reduce GI upset.,Report symptoms of thromboembolism (chest pain, leg swelling) immediately.,Use non-hormonal contraception due to teratogenicity and pregnancy disruption.,May cause weight gain, edema, acne, or voice deepening; notify doctor if severe.,Avoid alcohol due to potential hepatotoxicity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRAVELLE vs DANOCRINE, answered by our medical review team.
BRAVELLE is a Gonadotropin that works by Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.. DANOCRINE is a Androgen/Antigonadotropin that works by Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRAVELLE and DANOCRINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRAVELLE is: For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.. The standard adult dose of DANOCRINE is: 100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRAVELLE and DANOCRINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRAVELLE is classified as Category C. Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestatio. DANOCRINE is classified as Category C. Danocrine (danazol) is contraindicated in pregnancy. It is an androgen derivative and can cause virilization of the female fetus, including clitoromegaly, labial fusion, and urogen. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.